で公開中です！詳しく見る

Biote Corp

BTMD

時価総額 $3097万

1.08 USD

-0.03

2.7%

終値時点更新済み 10月16日 16:00 EDT

1日

-2.7%

5日間

-6.09%

1か月

-19.4%

3か月

-54.62%

6か月

-48.57%

年初来

-56.28%

1年

-62.76%

5年間

-88.91%

10年間

-89.25%

概要： Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

従業員数： 223

ヘルスケア医療施設

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

biote Corp. (BTMD) Q2 2026 Earnings Call Transcript

biote Corp. (BTMD) Q2 2026 Earnings Call Transcript

biote Corp. (BTMD) Q2 2026 Earnings Call Transcript

ニュートラル

Zacks Investment Research

biote Corp. (BTMD) Reports Break-Even Earnings for Q2

biote Corp. (BTMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.1 per share a year ago.

biote Corp. (BTMD) Reports Break-Even Earnings for Q2

ニュートラル

biote Q2 Earnings Call Highlights

biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half of 2026.

biote Q2 Earnings Call Highlights

ニュートラル

Biote Reports Second Quarter 2026 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the second quarter ended June 30, 2026. “Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterso.

Biote Reports Second Quarter 2026 Financial Results

ニュートラル

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide second quarter financial results on Wednesday, August 5, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET the same day. Conference Call Details The conference call may be acc.

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

ニュートラル

Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles with.

Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

ニュートラル

Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In.

Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

ニュートラル

biote Corp. (BTMD) Q1 2026 Earnings Call Transcript

biote Corp. (BTMD) Q1 2026 Earnings Call Transcript

biote Corp. (BTMD) Q1 2026 Earnings Call Transcript

ネガティブ

Zacks Investment Research

biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates

biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.

biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates

ニュートラル

Biote Reports First Quarter 2026 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the first quarter ended March 31, 2026. “During the first quarter of 2026, we continued to advance our strategic priorities and remained focused on our key objective of restoring sustainable procedure revenue growth,” said Bret Christensen, Biote's Chief Executive Officer. “.

Biote Reports First Quarter 2026 Financial Results

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています